Curt R. Fischer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Curt R. Fischer has a total of 155 co-authors. Here are the top co-authors by number of shared publications:
- Gregory Stephanopoulos
Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA
6 shared publications Elke Nevoigt
Department of Chemical Engineering, Massachusetts Institute of Technology, Room 56-469, Cambridge, Massachusetts 02139, USA
4 shared publications- Justin Laine Sonnenburg
Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, USA
4 shared publications - Trent R. Northen
Lawrence Berkeley National Laboratory
4 shared publications Benjamin P. Bowen
Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, United States
3 shared publications- Benjamin P. Bowen
Environmental Genomics and Systems Biology Division, Lawrence Berkeley National Laboratory, Berkeley, USA
3 shared publications
Latest Publications
- Open Access
- 29 May 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Specific derivatization of internal alkynes for improved electrospray analysis
Many plant and fungal species, including foods, produce specialized metabolites that contain internal alkynes. Specific detection and analysis of naturally produced internal alkynes is often difficult, because of poor ionization, thermal instability, and a lack of internal-alkyne-specific chemical tools to facilitate analysis. We developed a derivatization protocol for improved LC-MS analysis of internal alkynes. The method exploits the ruthenium-catalyzed azide-alkyne cycloaddition (RuAAC) reaction to form trisubstituted triazoles, species with vastly improved electrospray ionization efficiencies compared to many naturally occurring internal alkynes. The method can be used in crude biological extracts and other complex samples, and increases the ionization efficiency by up to 32,000-fold. Additionally, using a fast (1 minute), direct LC-MS analysis of RuAAC reactions during derivatization, we observed the kinetics of formation and depletion of variety of catalyst-derived ruthenium complexes, some of which may provide mechanistic insight into the limitations of the RuAAC derivatization. We use this derivatization in the course of isolating a dietary internal alkyne from a hedgehog mushroom. This molecule proved to be a previously unreported analog of repandiol.
- 29 May 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessSpecific derivatization of internal alkynes for improved electrospray analysis
Many plant and fungal species, including foods, produce specialized metabolites that contain internal alkynes. Specific detection and analysis of naturally produced internal alkynes is often difficult, because of poor ionization, thermal instability, and a lack of internal-alkyne-specific chemical tools to facilitate analysis. We developed a derivatization protocol for improved LC-MS analysis of internal alkynes. The method exploits the ruthenium-catalyzed azide-alkyne cycloaddition (RuAAC) reaction to form trisubstituted triazoles, species with vastly improved electrospray ionization efficiencies compared to many naturally occurring internal alkynes. The method can be used in crude biological extracts and other complex samples, and increases the ionization efficiency by up to 32,000-fold. Additionally, using a fast (1 minute), direct LC-MS analysis of RuAAC reactions during derivatization, we observed the kinetics of formation and depletion of variety of catalyst-derived ruthenium complexes, some of which may provide mechanistic insight into the limitations of the RuAAC derivatization. We use this derivatization in the course of isolating a dietary internal alkyne from a hedgehog mushroom. This molecule proved to be a previously unreported analog of repandiol.
- Open Access
- 6 January 2022
- Published by Springer Nature in Nature Metabolism
- Vol. 4 (1) , 19-28
Oxidative ornithine metabolism supports non-inflammatory C. difficile colonization
The enteric pathogen Clostridioides difficile (Cd) is responsible for a toxin-mediated infection that causes more than 200,000 recorded hospitalizations and 13,000 deaths in the United States every year1. However, Cd can colonize the gut in the absence of disease symptoms. Prevalence of asymptomatic colonization by toxigenic Cd in healthy populations is high; asymptomatic carriers are at increased risk of infection compared to noncolonized individuals and may be a reservoir for transmission of Cd infection2,3. Elucidating the molecular mechanisms by which Cd persists in the absence of disease is necessary for understanding pathogenesis and developing refined therapeutic strategies. Here, we show with gut microbiome metatranscriptomic analysis that mice recalcitrant to Cd infection and inflammation exhibit increased community-wide expression of arginine and ornithine metabolic pathways. To query Cd metabolism specifically, we leverage RNA sequencing in gnotobiotic mice infected with two wild-type strains (630 and R20291) and isogenic toxin-deficient mutants of these strains to differentiate inflammation-dependent versus -independent transcriptional states. A single operon encoding oxidative ornithine degradation is consistently upregulated across non-toxigenic Cd strains. Combining untargeted and targeted metabolomics with bacterial and host genetics, we demonstrate that both diet- and host-derived sources of ornithine provide a competitive advantage to Cd, suggesting a mechanism for Cd persistence within a non-inflammatory, healthy gut.
- 6 January 2022
- Published by Springer Nature in Nature Metabolism
- Vol. 4 (1) , 19-28
Open AccessOxidative ornithine metabolism supports non-inflammatory C. difficile colonization
The enteric pathogen Clostridioides difficile (Cd) is responsible for a toxin-mediated infection that causes more than 200,000 recorded hospitalizations and 13,000 deaths in the United States every year1. However, Cd can colonize the gut in the absence of disease symptoms. Prevalence of asymptomatic colonization by toxigenic Cd in healthy populations is high; asymptomatic carriers are at increased risk of infection compared to noncolonized individuals and may be a reservoir for transmission of Cd infection2,3. Elucidating the molecular mechanisms by which Cd persists in the absence of disease is necessary for understanding pathogenesis and developing refined therapeutic strategies. Here, we show with gut microbiome metatranscriptomic analysis that mice recalcitrant to Cd infection and inflammation exhibit increased community-wide expression of arginine and ornithine metabolic pathways. To query Cd metabolism specifically, we leverage RNA sequencing in gnotobiotic mice infected with two wild-type strains (630 and R20291) and isogenic toxin-deficient mutants of these strains to differentiate inflammation-dependent versus -independent transcriptional states. A single operon encoding oxidative ornithine degradation is consistently upregulated across non-toxigenic Cd strains. Combining untargeted and targeted metabolomics with bacterial and host genetics, we demonstrate that both diet- and host-derived sources of ornithine provide a competitive advantage to Cd, suggesting a mechanism for Cd persistence within a non-inflammatory, healthy gut.
- Top Cited Papers
- 14 July 2021
- Published by Springer Nature in Nature
- Vol. 595 (7867) , 415-420
A metabolomics pipeline for the mechanistic interrogation of the gut microbiome
Gut microorganisms modulate host phenotypes and are associated with numerous health effects in humans, ranging from host responses to cancer immunotherapy to metabolic disease and obesity. However, difficulty in accurate and high-throughput functional analysis of human gut microorganisms has hindered efforts to define mechanistic connections between individual microbial strains and host phenotypes. One key way in which the gut microbiome influences host physiology is through the production of small molecules1,2,3, yet progress in elucidating this chemical interplay has been hindered by limited tools calibrated to detect the products of anaerobic biochemistry in the gut. Here we construct a microbiome-focused, integrated mass-spectrometry pipeline to accelerate the identification of microbiota-dependent metabolites in diverse sample types. We report the metabolic profiles of 178 gut microorganism strains using our library of 833 metabolites. Using this metabolomics resource, we establish deviations in the relationships between phylogeny and metabolism, use machine learning to discover a previously undescribed type of metabolism in Bacteroides, and reveal candidate biochemical pathways using comparative genomics. Microbiota-dependent metabolites can be detected in diverse biological fluids from gnotobiotic and conventionally colonized mice and traced back to the corresponding metabolomic profiles of cultured bacteria. Collectively, our microbiome-focused metabolomics pipeline and interactive metabolomics profile explorer are a powerful tool for characterizing microorganisms and interactions between microorganisms and their host.
- 14 July 2021
- Published by Springer Nature in Nature
- Vol. 595 (7867) , 415-420
Top Cited PapersA metabolomics pipeline for the mechanistic interrogation of the gut microbiome
Gut microorganisms modulate host phenotypes and are associated with numerous health effects in humans, ranging from host responses to cancer immunotherapy to metabolic disease and obesity. However, difficulty in accurate and high-throughput functional analysis of human gut microorganisms has hindered efforts to define mechanistic connections between individual microbial strains and host phenotypes. One key way in which the gut microbiome influences host physiology is through the production of small molecules1,2,3, yet progress in elucidating this chemical interplay has been hindered by limited tools calibrated to detect the products of anaerobic biochemistry in the gut. Here we construct a microbiome-focused, integrated mass-spectrometry pipeline to accelerate the identification of microbiota-dependent metabolites in diverse sample types. We report the metabolic profiles of 178 gut microorganism strains using our library of 833 metabolites. Using this metabolomics resource, we establish deviations in the relationships between phylogeny and metabolism, use machine learning to discover a previously undescribed type of metabolism in Bacteroides, and reveal candidate biochemical pathways using comparative genomics. Microbiota-dependent metabolites can be detected in diverse biological fluids from gnotobiotic and conventionally colonized mice and traced back to the corresponding metabolomic profiles of cultured bacteria. Collectively, our microbiome-focused metabolomics pipeline and interactive metabolomics profile explorer are a powerful tool for characterizing microorganisms and interactions between microorganisms and their host.
- Open Access
A metabolomics pipeline enables mechanistic interrogation of the gut microbiome
Gut microbes modulate host phenotypes and are associated with numerous health effects in humans, ranging from cancer immunotherapy response to metabolic disease and obesity. However, difficulty in accurate and high-throughput functional analysis of human gut microbes has hindered defining mechanistic connections between individual microbial strains and host phenotypes. One key way the gut microbiome influences host physiology is through the production of small molecules 1–3 , yet progress in elucidating this chemical interplay has been hindered by limited tools calibrated to detect products of anaerobic biochemistry in the gut. Here we construct a microbiome-focused, integrated mass-spectrometry pipeline to accelerate the identification of microbiota-dependent metabolites (MDMs) in diverse sample types. We report the metabolic profiles of 178 gut microbe strains using our library of 833 metabolites. Leveraging this metabolomics resource we establish deviations in the relationships between phylogeny and metabolism, use machine learning to discover novel metabolism in Bacteroides , and employ comparative genomics-based discovery of candidate biochemical pathways. MDMs can be detected in diverse biofluids in gnotobiotic and conventional mice and traced back to corresponding metabolomic profiles of cultured bacteria. Collectively, our microbiome-focused metabolomics pipeline and interactive metabolomics profile explorer are a powerful tool for characterizing microbe and microbe-host interactions.
Open AccessA metabolomics pipeline enables mechanistic interrogation of the gut microbiome
Gut microbes modulate host phenotypes and are associated with numerous health effects in humans, ranging from cancer immunotherapy response to metabolic disease and obesity. However, difficulty in accurate and high-throughput functional analysis of human gut microbes has hindered defining mechanistic connections between individual microbial strains and host phenotypes. One key way the gut microbiome influences host physiology is through the production of small molecules 1–3 , yet progress in elucidating this chemical interplay has been hindered by limited tools calibrated to detect products of anaerobic biochemistry in the gut. Here we construct a microbiome-focused, integrated mass-spectrometry pipeline to accelerate the identification of microbiota-dependent metabolites (MDMs) in diverse sample types. We report the metabolic profiles of 178 gut microbe strains using our library of 833 metabolites. Leveraging this metabolomics resource we establish deviations in the relationships between phylogeny and metabolism, use machine learning to discover novel metabolism in Bacteroides , and employ comparative genomics-based discovery of candidate biochemical pathways. MDMs can be detected in diverse biofluids in gnotobiotic and conventional mice and traced back to corresponding metabolomic profiles of cultured bacteria. Collectively, our microbiome-focused metabolomics pipeline and interactive metabolomics profile explorer are a powerful tool for characterizing microbe and microbe-host interactions.
- Open Access
Identification of polyketide biosynthetic gene clusters that harbor self-resistance target genes
Background: Polyketide secondary metabolites have been a rich source of antibiotic discovery for decades. Thousands of novel polyketide synthase (PKS) gene clusters have been identified in recent years with advances in DNA sequencing. However, experimental characterization of novel and useful PKS activities remains complicated. As a result, computational tools to analyze sequence data are essential to identify and prioritize potentially novel PKS activities. Here we exploit the concept of genetically-encoded self-resistance to identify and rank biosynthetic gene clusters for their potential to encode novel antibiotics. Results: To identify PKS genes that are likely to produce an antibacterial compound, we developed an automated method to identify and catalog clusters that harbor potential self-resistance genes. We manually curated a list of known self-resistance genes and searched all NCBI genome databases for homologs of these self-resistance genes in biosynthetic gene clusters. The algorithm takes into account (1) the distance of the potential self-resistance gene to a core enzyme in the biosynthetic gene cluster; (2) the presence of a duplicated housekeeping copy of the self-resistance gene; (3) the presence of close homologs of the biosynthetic gene cluster in diverse species also harboring the putative self-resistance gene; (4) evidence for coevolution of the self-resistance gene and core biosynthetic gene; and (5) self-resistance gene ubiquity. We generated a catalog of 190 unique PKS clusters whose products likely target known enzymes of antibacterial importance. We also present an expanded set of putative self-resistance genes that may be useful in identifying small molecules active against novel microbial targets. Conclusions: We developed a bioinformatic approach to identify and rank biosynthetic gene clusters that likely harbor self-resistance genes and may produce compounds with antibacterial properties. We compiled a list of putative self-resistance genes for novel antibacterial targets, and of orphan PKS clusters harboring these targets. These catalogues are a resource for discovery of novel antibiotics.
Open AccessIdentification of polyketide biosynthetic gene clusters that harbor self-resistance target genes
Background: Polyketide secondary metabolites have been a rich source of antibiotic discovery for decades. Thousands of novel polyketide synthase (PKS) gene clusters have been identified in recent years with advances in DNA sequencing. However, experimental characterization of novel and useful PKS activities remains complicated. As a result, computational tools to analyze sequence data are essential to identify and prioritize potentially novel PKS activities. Here we exploit the concept of genetically-encoded self-resistance to identify and rank biosynthetic gene clusters for their potential to encode novel antibiotics. Results: To identify PKS genes that are likely to produce an antibacterial compound, we developed an automated method to identify and catalog clusters that harbor potential self-resistance genes. We manually curated a list of known self-resistance genes and searched all NCBI genome databases for homologs of these self-resistance genes in biosynthetic gene clusters. The algorithm takes into account (1) the distance of the potential self-resistance gene to a core enzyme in the biosynthetic gene cluster; (2) the presence of a duplicated housekeeping copy of the self-resistance gene; (3) the presence of close homologs of the biosynthetic gene cluster in diverse species also harboring the putative self-resistance gene; (4) evidence for coevolution of the self-resistance gene and core biosynthetic gene; and (5) self-resistance gene ubiquity. We generated a catalog of 190 unique PKS clusters whose products likely target known enzymes of antibacterial importance. We also present an expanded set of putative self-resistance genes that may be useful in identifying small molecules active against novel microbial targets. Conclusions: We developed a bioinformatic approach to identify and rank biosynthetic gene clusters that likely harbor self-resistance genes and may produce compounds with antibacterial properties. We compiled a list of putative self-resistance genes for novel antibacterial targets, and of orphan PKS clusters harboring these targets. These catalogues are a resource for discovery of novel antibiotics.
- Open Access
- 9 April 2020
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 9
Cooperative enzymatic control of N-acyl amino acids by PM20D1 and FAAH
The N-acyl amino acids are a family of bioactive lipids with pleiotropic physiologic functions, including in energy homeostasis. Their endogenous levels are regulated by an extracellular mammalian N-acyl amino acid synthase/hydrolase called PM20D1 (peptidase M20 domain containing 1). Using an activity-guided biochemical approach, we report the molecular identification of fatty acid amide hydrolase (FAAH) as a second intracellular N-acyl amino acid synthase/hydrolase. In vitro, FAAH exhibits a more restricted substrate scope compared to PM20D1. In mice, genetic ablation or selective pharmacological inhibition of FAAH bidirectionally dysregulates intracellular, but not circulating, N-acyl amino acids. Dual blockade of both PM20D1 and FAAH reveals a dramatic and non-additive biochemical engagement of these two enzymatic pathways. These data establish FAAH as a second intracellular pathway for N-acyl amino acid metabolism and underscore enzymatic division of labor as an enabling strategy for the regulation of a structurally diverse bioactive lipid family.
- 9 April 2020
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 9
Open AccessCooperative enzymatic control of N-acyl amino acids by PM20D1 and FAAH
The N-acyl amino acids are a family of bioactive lipids with pleiotropic physiologic functions, including in energy homeostasis. Their endogenous levels are regulated by an extracellular mammalian N-acyl amino acid synthase/hydrolase called PM20D1 (peptidase M20 domain containing 1). Using an activity-guided biochemical approach, we report the molecular identification of fatty acid amide hydrolase (FAAH) as a second intracellular N-acyl amino acid synthase/hydrolase. In vitro, FAAH exhibits a more restricted substrate scope compared to PM20D1. In mice, genetic ablation or selective pharmacological inhibition of FAAH bidirectionally dysregulates intracellular, but not circulating, N-acyl amino acids. Dual blockade of both PM20D1 and FAAH reveals a dramatic and non-additive biochemical engagement of these two enzymatic pathways. These data establish FAAH as a second intracellular pathway for N-acyl amino acid metabolism and underscore enzymatic division of labor as an enabling strategy for the regulation of a structurally diverse bioactive lipid family.
- Open Access
Enhancing the Antiviral Efficacy of RNA-Dependent RNA Polymerase Inhibition by Combination with Modulators of Pyrimidine Metabolism
Genome-wide analysis of the mode of action of GSK983, a potent antiviral agent, led to the identification of dihydroorotate dehydrogenase (DHODH) as its target, along with the discovery that knockdown of genes in pyrimidine salvage pathways sensitized cells to GSK983. Because GSK983 is an ineffective antiviral in the presence of physiological uridine concentrations, we explored combining GSK983 with pyrimidine salvage inhibitors. We synthesized and evaluated analogs of cyclopentenyl uracil (CPU), an inhibitor of uridine salvage. We found that CPU was efficiently converted into its triphosphates in cells. When combined with GSK983, it led to large drops in cellular UTP and CTP pools. Consequently, CPU-GSK983 suppressed dengue virus replication in the presence of physiological concentrations of uridine. In addition, the CPU-GSK983 combination markedly enhanced the effect of RNA-dependent RNA polymerase (RdRp) inhibition on viral genome infection. Our findings highlight a new host-targeting strategy for potentiating the antiviral activities of RdRp inhibitors.
Open AccessEnhancing the Antiviral Efficacy of RNA-Dependent RNA Polymerase Inhibition by Combination with Modulators of Pyrimidine Metabolism
Genome-wide analysis of the mode of action of GSK983, a potent antiviral agent, led to the identification of dihydroorotate dehydrogenase (DHODH) as its target, along with the discovery that knockdown of genes in pyrimidine salvage pathways sensitized cells to GSK983. Because GSK983 is an ineffective antiviral in the presence of physiological uridine concentrations, we explored combining GSK983 with pyrimidine salvage inhibitors. We synthesized and evaluated analogs of cyclopentenyl uracil (CPU), an inhibitor of uridine salvage. We found that CPU was efficiently converted into its triphosphates in cells. When combined with GSK983, it led to large drops in cellular UTP and CTP pools. Consequently, CPU-GSK983 suppressed dengue virus replication in the presence of physiological concentrations of uridine. In addition, the CPU-GSK983 combination markedly enhanced the effect of RNA-dependent RNA polymerase (RdRp) inhibition on viral genome infection. Our findings highlight a new host-targeting strategy for potentiating the antiviral activities of RdRp inhibitors.
- 13 December 2019
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 366 (6471) , 1331-+
Depletion of microbiome-derived molecules in the host using Clostridium genetics
Clostridial metabolite production: The clostridia are Firmicute bacterial commensals commonly found in the mammalian gut. Clostridia produce a range of metabolites that diffuse into the host's circulation and have been difficult to manipulate genetically, but Guo et al. successfully developed a CRISPR-Cas9 deletion system in Clostridium sporogenes (see the Perspective by Henke and Clardy). The authors used deletion mutants and mass spectrometry to elucidate clostridial synthesis of several different branched short-chain fatty acids (SCFAs), including isobutyrate, 2-methylbutyrate, and isovalerate. Germ-free mice colonized with mutants incapable of synthesizing SCFAs showed altered immunoglobulin A production. This finding potentially links bacterial SCFA production and host responses to the presence of the clostridia. Science , this issue p. eaav1282 ; see also p. 1309
- 13 December 2019
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 366 (6471) , 1331-+
Depletion of microbiome-derived molecules in the host using Clostridium genetics
Clostridial metabolite production: The clostridia are Firmicute bacterial commensals commonly found in the mammalian gut. Clostridia produce a range of metabolites that diffuse into the host's circulation and have been difficult to manipulate genetically, but Guo et al. successfully developed a CRISPR-Cas9 deletion system in Clostridium sporogenes (see the Perspective by Henke and Clardy). The authors used deletion mutants and mass spectrometry to elucidate clostridial synthesis of several different branched short-chain fatty acids (SCFAs), including isobutyrate, 2-methylbutyrate, and isovalerate. Germ-free mice colonized with mutants incapable of synthesizing SCFAs showed altered immunoglobulin A production. This finding potentially links bacterial SCFA production and host responses to the presence of the clostridia. Science , this issue p. eaav1282 ; see also p. 1309
- 26 August 2019
- Published by Springer Nature in Nature Chemical Biology
- Vol. 15 (10) , 949-958
CRISPR-Cas9 screens identify regulators of antibody–drug conjugate toxicity
Antibody–drug conjugates (ADCs) selectively deliver chemotherapeutic agents to target cells and are important cancer therapeutics. However, the mechanisms by which ADCs are internalized and activated remain unclear. Using CRISPR-Cas9 screens, we uncover many known and novel endolysosomal regulators as modulators of ADC toxicity. We identify and characterize C18ORF8/RMC1 as a regulator of ADC toxicity through its role in endosomal maturation. Through comparative analysis of screens with ADCs bearing different linkers, we show that a subset of late endolysosomal regulators selectively influence toxicity of noncleavable linker ADCs. Surprisingly, we find cleavable valine–citrulline linkers can be processed rapidly after internalization without lysosomal delivery. Lastly, we show that sialic acid depletion enhances ADC lysosomal delivery and killing in diverse cancer cell types, including with FDA (US Food and Drug Administration)-approved trastuzumab emtansine (T-DM1) in Her2-positive breast cancer cells. Together, these results reveal new regulators of endolysosomal trafficking, provide important insights for ADC design and identify candidate combination therapy targets.
- 26 August 2019
- Published by Springer Nature in Nature Chemical Biology
- Vol. 15 (10) , 949-958
CRISPR-Cas9 screens identify regulators of antibody–drug conjugate toxicity
Antibody–drug conjugates (ADCs) selectively deliver chemotherapeutic agents to target cells and are important cancer therapeutics. However, the mechanisms by which ADCs are internalized and activated remain unclear. Using CRISPR-Cas9 screens, we uncover many known and novel endolysosomal regulators as modulators of ADC toxicity. We identify and characterize C18ORF8/RMC1 as a regulator of ADC toxicity through its role in endosomal maturation. Through comparative analysis of screens with ADCs bearing different linkers, we show that a subset of late endolysosomal regulators selectively influence toxicity of noncleavable linker ADCs. Surprisingly, we find cleavable valine–citrulline linkers can be processed rapidly after internalization without lysosomal delivery. Lastly, we show that sialic acid depletion enhances ADC lysosomal delivery and killing in diverse cancer cell types, including with FDA (US Food and Drug Administration)-approved trastuzumab emtansine (T-DM1) in Her2-positive breast cancer cells. Together, these results reveal new regulators of endolysosomal trafficking, provide important insights for ADC design and identify candidate combination therapy targets.
- 11 June 2019
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 141 (24) , 9474-9478
Tunable Enzymatic Synthesis of the Immunomodulator Lipid IVA To Enable Structure–Activity Analysis
The Lipid A family of glycolipids, found in the outer membranes of all Gram-negative bacteria, exhibits considerable structural diversity in both lipid and glycan moieties. The lack of facile methods to prepare analogs of these natural products represents a major roadblock in understanding the relationship between their structure and immunomodulatory activities. Here we present a modular, cell-free multi-enzymatic platform to access these structure-activity relationships. By individually purifying 19 Escherichia coli proteins and reconstituting them in vitro in the presence of acetyl-CoA, UDP-N-acetylglucosamine, NADPH, and ATP, we have developed a system capable of synthesizing Lipid IVA, the first bioactive intermediate in the Lipid A pathway. Carry-over of contaminant glycolipids from expression host strains was minimized by careful chromatographic purification of proteins as well as products. Our reconstituted multi-enzyme system revealed considerable promiscuity for orthologs with distinct substrate specificity, as illustrated by swapping enzymes from distantly related cyanobacterial and Pseudomonas species. Analysis of the agonistic and antagonistic activities of the resulting products against the THP-1 human monocytic cell line revealed hitherto unrecognized trends, while opening the door to harnessing the potent biological activities of these complex glycolipid natural products.
- 11 June 2019
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 141 (24) , 9474-9478
Tunable Enzymatic Synthesis of the Immunomodulator Lipid IVA To Enable Structure–Activity Analysis
The Lipid A family of glycolipids, found in the outer membranes of all Gram-negative bacteria, exhibits considerable structural diversity in both lipid and glycan moieties. The lack of facile methods to prepare analogs of these natural products represents a major roadblock in understanding the relationship between their structure and immunomodulatory activities. Here we present a modular, cell-free multi-enzymatic platform to access these structure-activity relationships. By individually purifying 19 Escherichia coli proteins and reconstituting them in vitro in the presence of acetyl-CoA, UDP-N-acetylglucosamine, NADPH, and ATP, we have developed a system capable of synthesizing Lipid IVA, the first bioactive intermediate in the Lipid A pathway. Carry-over of contaminant glycolipids from expression host strains was minimized by careful chromatographic purification of proteins as well as products. Our reconstituted multi-enzyme system revealed considerable promiscuity for orthologs with distinct substrate specificity, as illustrated by swapping enzymes from distantly related cyanobacterial and Pseudomonas species. Analysis of the agonistic and antagonistic activities of the resulting products against the THP-1 human monocytic cell line revealed hitherto unrecognized trends, while opening the door to harnessing the potent biological activities of these complex glycolipid natural products.